Navigation Links
BiOptix announces low cost Surface Plasmon Resonance Services for Colorado-based researchers
Date:7/9/2013

BOULDER, Colo., July 8, 2013 /PRNewswire/ -- BiOptix formally announces a unique to the industry research collaboration with the Biophysics Shared Resource Core Facility at the University of Colorado Denver, Anschutz Medical Campus.  The collaboration, which is supported by BiOptix, is offering low cost SPR services for Colorado-based researchers on the new BiOptix 404pi, a next-generation surface plasmon resonance platform designed and built in Colorado.  The BiOptix 404pi provides label-free analysis of protein-protein kinetics as well as protein-small molecule interactions.

"We are proud to partner with and support the Biophysics Shared Resource Facility at the University of Colorado," noted Ken Wilczek, Vice President of Sales and Marketing for BiOptix.  "By offering the use of the new BiOptix 404pi to researchers based in Colorado, BiOptix can both support as well as foster scientific research and activity here in our home state."  Researchers from academia as well as industry, who are based in or have principal activities in Colorado, are invited to participate in the program.   

The Biophysics Shared Resource Facility is a user facility owned and operated by the Program in Structural Biology and Biochemistry at the University of Colorado, Denver.  Since opening in 2001, the group has developed resources to study biomolecular structure and thermodynamics through surface plasmon resonance, CD/ORD, ITC, DSC, fluorescence spectroscopy, and analytical ultracentrifugation (AUC).  In addition, the group also offers mass spectroscopy, LC/MS/MS, HPLC and amino acid analysis services.  Additional information about the facility as well as the program supported by BiOptix can be found via the following link:  http://www.ucdenver.edu/academics/colleges/medicalschool/programs/biomol/strucbiocores/biophysics/Pages/biophysicscorefacilities.aspx

Surface Plasmon Resonance is an advanced and highly sensitive optical technology that measures refractive index changes on a sensor chip's gold surface due to a change in mass that occurs during a binding event. This change can be used to monitor biological interactions such as the concentration of target molecules, kinetic rates and affinity constants. BiOptix has developed and patented a novel ultra-sensitive detection platform known as Enhanced Surface Plasmon resonance, or ESPR. Unlike traditional SPR, ESPR instrumentation from BiOptix enables the high sensitivity of SPR with the high stability and lower noise of common path interferometry.

About BiOptix

BiOptix Diagnostics is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures, Remeditex and Rusnano.  BiOptix has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR – Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction—with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at:  www.bioptix.com


'/>"/>
SOURCE BiOptix
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BiOptix to highlight new carbonic anhydrase data at IBCs Biopharmaceutical Development & Production Week
2. BiOptix announces expansion of Innovators Program at Molecular Med TRI-CON 2013
3. BiOptix Announces Fall 2012 Tradeshow and Symposia Schedule
4. Depomed Announces Appointment of Louis J. Lavigne, Jr. to Board of Directors
5. Blue Sky BioServices Expands its Executive Team - Announces Appointment of Ted Marple as President and CEO
6. Concord Medical Announces Launch of Mobile Health Application
7. Upsher-Smith Announces Patient Enrollment In Open-label Safety Study Of USL261 (Intranasal Midazolam) For Rescue Treatment Of Seizure Clusters In Epilepsy
8. Valeant Pharmaceuticals Announces Closing of Public Offering of Common Shares
9. Anthera Announces Initiation of BRIGHT-SC Phase 2 Clinical Study in IgA Nephropathy with Blisibimod
10. Simcere Pharmaceutical Group Announces Sale of Equity Interest in Boda
11. LipoScience Announces Data Presented at the 2013 American Diabetes Association Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... Deutschland und GERMANTOWN, Maryland , ... Zusammenarbeit mit Therawis bedient dringenden ...   QIAGEN N.V. (NASDAQ: ... bekannt, eine Lizenz- und Entwicklungsvereinbarung mit Therawis Diagnostics ... die Onkologie eingegangen zu sein. Ein erstes Projekt ...
(Date:5/25/2016)... 2016  Zymo Research Corp. announced today the ... materials that help researchers obtain the most accurate ... The rapid growth of the study of microbiomes ... standard methods to improve the reproducibility and quality ... at every step of the measurement process including ...
(Date:5/25/2016)... , May 25, 2016 ... Size, Share, Development, Growth and Demand Forecast to 2022 ... Insulin Pump and Others)" published by P&S Market Research, ... $9,998.3 million in 2015, and it is expected to ... on type, the insulin pump segment is expected to ...
Breaking Medicine Technology:
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... There was a time when tampons and ... going with the flow and turning to menstrual cups, like Lunette . To make ... is introducing their new anthem in this catchy video ! , It’s easy ...
(Date:5/25/2016)... ... 25, 2016 , ... Dr. Travis Schwarz is an experienced dentist who leads ... MO 63366. He serves patients of all ages with a full menu of dental ... is reflected in the superior patient reviews that he has consistently earned during his ...
(Date:5/25/2016)... , ... May 25, 2016 , ... ... services and products in the developing world, is pleased to release their 2015 ... over 5 million unwanted pregnancies, almost 14,000 maternal deaths and 3.8 million unsafe ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... its annual Medical and Prescription Drug survey , an employee benefits ... survey, which was conducted in December 2015, indicates that employers are turning to ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... "FCPX LUT ... quality of your footage," said Christina Austin - CEO of Pixel Film Studios. ... can quickly and easily add stylish color grades to their footage. A LUT is ...
Breaking Medicine News(10 mins):